Impact of hypertension on mortality in patients with ST-elevation myocardial infarction undergoing primary angioplasty: insights from the international multicenter ISACS-STEMI registry.

Journal

Journal of hypertension

ISSN: 1473-5598

Titre abrégé: J Hypertens

Pays: Netherlands

ID NLM: 8306882

Informations de publication

Date de publication:
14 Oct 2024

Historique:

received: 23 03 2024

accepted: 04 07 2024

medline: 24 10 2024

pubmed: 24 10 2024

entrez: 24 10 2024

Statut: aheadofprint

Résumé

Hypertension is the most prevalent cardiovascular risk factor, with several detrimental effects on the cardiovascular system. Contrasting results have been reported so far on its prognostic role in patients admitted for ST-segment elevation myocardial infarction (STEMI). Therefore, we investigated the impact of hypertension on short-term mortality in a large multicenter contemporary registry of STEMI patients, including patients treated during COVID-19 pandemic. The ISACS-STEMI COVID-19 was a retrospective registry that included STEMI patients treated with primary percutaneous coronary intervention (PCI) between March and June of 2019 and 2020 in 109 high-volume primary PCI centers from 4 continents. We collected data on baseline, clinical and procedural characteristics, in-hospital outcome and 30-day mortality. For this analysis patients were grouped according to history of hypertension at admission. A total of 16083 patients were assessed, including 8813 (54.8%) with history of hypertension. These patients were more often elderly, with a worse cardiovascular risk profile, but were less frequently active smoker. Some procedural differences were observed between the two groups, including lower rate of thrombectomy and use of glycoprotein IIb/IIIa inhibitors or cangrelor but more extensive coronary disease in patients with hypertension. Between patients with and without hypertension, there was no significant difference in SARS-CoV-2 positivity. Hypertensive patients had a significantly higher in-hospital and 30-day mortality, similarly observed in both pre-COVID-19 and COVID-19 era, and confirmed after adjustment for main baseline differences and propensity score (in-hospital mortality: adjusted odds ratio (OR) [95% confidence interval (CI)] =1.673 [1.389-2.014], P < 0.001; 30-day mortality: adjusted hazard ratio (HR) [95% CI] = 1.418 [1.230-1.636], P < 0.001). This is one of the largest and contemporary study assessing the impact of hypertension in STEMI patients undergoing primary angioplasty, including also the COVID-19 pandemic period. Hypertension was independently associated with significantly higher rates of in-hospital and 30-day mortality.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

The ISACS-STEMI COVID-19 was a retrospective registry that included STEMI patients treated with primary percutaneous coronary intervention (PCI) between March and June of 2019 and 2020 in 109 high-volume primary PCI centers from 4 continents. We collected data on baseline, clinical and procedural characteristics, in-hospital outcome and 30-day mortality. For this analysis patients were grouped according to history of hypertension at admission.

RESULTS RESULTS

A total of 16083 patients were assessed, including 8813 (54.8%) with history of hypertension. These patients were more often elderly, with a worse cardiovascular risk profile, but were less frequently active smoker. Some procedural differences were observed between the two groups, including lower rate of thrombectomy and use of glycoprotein IIb/IIIa inhibitors or cangrelor but more extensive coronary disease in patients with hypertension. Between patients with and without hypertension, there was no significant difference in SARS-CoV-2 positivity. Hypertensive patients had a significantly higher in-hospital and 30-day mortality, similarly observed in both pre-COVID-19 and COVID-19 era, and confirmed after adjustment for main baseline differences and propensity score (in-hospital mortality: adjusted odds ratio (OR) [95% confidence interval (CI)] =1.673 [1.389-2.014], P < 0.001; 30-day mortality: adjusted hazard ratio (HR) [95% CI] = 1.418 [1.230-1.636], P < 0.001).

CONCLUSION CONCLUSIONS

This is one of the largest and contemporary study assessing the impact of hypertension in STEMI patients undergoing primary angioplasty, including also the COVID-19 pandemic period. Hypertension was independently associated with significantly higher rates of in-hospital and 30-day mortality.

Identifiants

DOI: 10.1097/HJH.0000000000003890 PMID: 39445586

pubmed: 39445586

doi: 10.1097/HJH.0000000000003890

pii: 00004872-990000000-00562

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–80.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39:3021–3104.

Favero G, Paini A, De Ciuceis C, Rodella LF, Moretti E, Porteri E, et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with essential hypertension. Blood Press 2018; 27:231–239.

Gronewold J, Kropp R, Lehmann N, Stang A, Mahabadi AA, Kälsch H, et al. Cardiovascular risk and atherosclerosis progression in hypertensive persons treated to blood pressure targets. Hypertension 2019; 74:1436–1447.

Flesch M, Hagemeister J, Berger H-J, Schiefer A, Schynkowski S, Klein M, et al. Implementation of guidelines for the treatment of acute ST-elevation myocardial infarction. Circ Cardiovasc Interv 2008; 1:95–102.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. J Hypertens 2015; 33:195–211.

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018; 39:119–177.

Verdoia M, Pergolini P, Rolla R, Nardin M, Schaffer A, Barbieri L, et al. Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. J Thromb Haemost 2016; 14:57–64.

Schoos MM, De Luca G, Dangas GD, Clemmensen P, Ayele GM, Mehran R, et al. Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial. EuroIntervention 2016; 12:1144–1153.

De Luca G, Navarese EP, Cassetti E, Verdoia M, Suryapranata H. Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol 2011; 107:198–203.

De Luca G, Schaffer A, Wirianta J, Suryapranata H. Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI. Int J Cardiol 2013; 168:2070–2081.

Costa F, Montalto C, Branca M, Hong S-J, Watanabe H, Franzone A, et al. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials. Eur Heart J 2023; 44:954–968.

Timmer JR, van der Horst ICC, de Luca G, Ottervanger JP, Hoorntje JCA, de Boer M-J, et al. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol 2005; 95:1375–1377.

Prasad A, Gersh BJ, Mehran R, Brodie BR, Brener SJ, Dizon JM, et al. Effect of ischemia duration and door-to-balloon time on myocardial perfusion in ST-segment elevation myocardial infarction: an analysis from HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). JACC Cardiovasc Interv 2015; 8:1966–1974.

De Luca G, Suryapranata H, Thomas K, van ’t Hof AWJ, de Boer MJ, Hoorntje JCA, et al. Outcome in patients treated with primary angioplasty for acute myocardial infarction due to left main coronary artery occlusion. Am J Cardiol 2003; 91:235–238.

De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, et al. Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation. Diabetes Care 2013; 36:1020–1025.

De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, et al. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost 2013; 110:826–833.

Pedersen F, Butrymovich V, Kelbæk H, Wachtell K, Helqvist S, Kastrup J, et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol 2014; 64:2101–2108.

De Luca G, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, et al. High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis 2011; 31:458–463.

Barbato E, Piscione F, Bartunek J, Galasso G, Cirillo P, De Luca G, et al. Role of beta2 adrenergic receptors in human atherosclerotic coronary arteries. Circulation 2005; 111:288–294.

Dzau VJ, Hodgkinson CP. RNA therapeutics for the cardiovascular system. Circulation 2024; 149:707–716.

Abrignani MG, Dominguez LJ, Biondo G, Di Girolamo A, Novo G, Barbagallo M, et al. In-hospital complications of acute myocardial infarction in hypertensive subjects. Am J Hypertens 2005; 18 (2 Pt 1):165–170.

Majahalme SK, Smith DE, Cooper JV, Kline-Rogers E, Mehta RH, Eagle KA, et al. Comparison of patients with acute coronary syndrome with and without systemic hypertension. Am J Cardiol 2003; 92:258–263.

Fresco C, Avanzini F, Bosi S, Franzosi MG, Maggioni AP, Santoro L, et al. Prognostic value of a history of hypertension in 11,483 patients with acute myocardial infarction treated with thrombolysis. GISSI-2 Investigators. Gruppo Italiano per lo Studio della, Sopravvivena nell’Infarto Miocardico. J Hypertens 1996; 14:743–750.

De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, et al. Impact of hypertension on clinical outcome in STEMI patients undergoing primary angioplasty with BMS or DES. Int J Cardiol 2014; 175:50–54.

De Luca G, van’t Hof AWJ, Huber K, Gibson CM, Bellandi F, Arntz H-R, et al. Impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplasty. Am J Cardiol 2013; 112:1083–1086.

Hoffmann F, Fassbender P, Zander W, Ulbrich L, Kuhr K, Adler C, et al. The hypertension paradox: survival benefit after ST-elevation myocardial infarction in patients with history of hypertension. a prospective cohort- and risk-analysis. Front Cardiovasc Med 2022; 9:785657.

Cecchi E, D’Alfonso MG, Chiostri M, Parigi E, Landi D, Valente S, et al. Impact of hypertension history on short and long-term prognosis in patients with acute myocardial infarction treated with percutaneous angioplasty: comparison between STEMI and NSTEMI. High Blood Press Cardiovasc Prev 2014; 21:37–43.

Konstantinou K, Tsioufis C, Koumelli A, Mantzouranis M, Kasiakogias A, Doumas M, et al. Hypertension and patients with acute coronary syndrome: putting blood pressure levels into perspective. J Clin Hypertens 2019; 21:1135–1143.

De Luca G, Verdoia M, Cercek M, Jensen LO, Vavlukis M, Calmac L, et al. Impact of COVID-19 pandemic on mechanical reperfusion for patients with STEMI. J Am Coll Cardiol 2020; 76:2321–2330.

De Luca G, Algowhary M, Uguz B, Oliveira DC, Ganyukov V, Zimbakov Z, et al. COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. Heart 2022; 108:458–466.

De Luca G, Algowhary M, Uguz B, Oliveira D, Ganyukov V, Zimbakov Z, et al. Impact of smoking status on mortality in STEMI patients undergoing mechanical reperfusion for STEMI: insights from the ISACS–STEMI COVID-19 registry. J Clin Med 2022; 11:6722.

De Luca G, Algowhary M, Uguz B, Oliveira DC, Ganyukov V, Zimbakov Z, et al. SARS-CoV-2 positivity, stent thrombosis, and 30-day mortality in STEMI patients undergoing mechanical reperfusion. Angiology 2023; 74:987–996.

De Luca G, Nardin M, Algowhary M, Uguz B, Oliveira DC, Ganyukov V, et al. Impact of chronic obstructive pulmonary disease on short-term outcome in patients with ST-elevation myocardial infarction during COVID-19 pandemic: insights from the international multicenter ISACS-STEMI registry. Respir Res 2022; 23:207.

Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Associat. J Hypertens 2023; 41:1874–2071.

Dumaine R, Gibson CM, Murphy SA, Southard M, Ly HQ, McCabe CH, et al. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich) 2006; 8:315–322.

Lazzeri C, Valente S, Chiostri M, Attanà P, Picariello C, Gensini GF. Impact of hypertension on short- and long-term prognoses in patients with ST elevation myocardial infarction and without previously known diabetes. Heart Vessels 2012; 27:370–376.

Erne P, Radovanovic D, Schoenenberger AW, Bertel O, Kaeslin T, Essig M, et al. Impact of hypertension on the outcome of patients admitted with acute coronary syndrome. J Hypertens 2015; 33:860–867.

Nardin M, Verdoia M, Laera N, Cao D, De Luca G. New insights into pathophysiology and new risk factors for ACS. J Clin Med 2023; 12:2883.

Porteri E, Rizzoni D, Mulvany MJ, De Ciuceis C, Sleiman I, Boari GE, et al. Adrenergic mechanisms and remodeling of subcutaneous small resistance arteries in humans. J Hypertens 2003; 21:2345–2352.

Santulli G, Campanile A, Spinelli L, Assante di Panzillo E, Ciccarelli M, Trimarco B, et al. G protein-coupled receptor kinase 2 in patients with acute myocardial infarction. Am J Cardiol 2011; 107:1125–1130.

Zheng D, Liu J, Piao H, Zhu Z, Wei R, Liu K. ROS-triggered endothelial cell death mechanisms: focus on pyroptosis, parthanatos, and ferroptosis. Front Immunol 2022; 13:1039241.

le Noble FA, Stassen FR, Hacking WJ, Struijker Boudier HA. Angiogenesis and hypertension. J Hypertens 1998; 16:1563–1572.

Parodi G, Carrabba N, Santoro GM, Memisha G, Valenti R, Buonamici P, et al. Heart failure and left ventricular remodeling after reperfused acute myocardial infarction in patients with hypertension. Hypertension 2006; 47:706–710.

Kapila R, Mahajan RP. Diastolic dysfunction. Contin Educ Anaesth Crit Care Pain 2009; 9:29–33.

Villars PS, Hamlin SK, Shaw AD, Kanusky JT. Role of diastole in left ventricular function, I: biochemical and biomechanical events. Am J Crit Care 2004; 13:394–403. quiz 404–5.

Rizzoni D, Agabiti-Rosei C, De Ciuceis C. State of the art review: vascular remodeling in hypertension. Am J Hypertens 2023; 36:1–13.

De Luca G, Nardin M, Algowhary M, Uguz B, Oliveira DC, Ganyukov V, et al. Renin-angiotensin system inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID-19 pandemic. Diabetes Epidemiol Manag 2021; 4:100022.

Rizzoni D, Porteri E, Boari GEM, De Ciuceis C, Sleiman I, Muiesan ML, et al. Prognostic significance of small-artery structure in hypertension. Circulation 2003; 108:2230–2235.

De Ciuceis C, Agabiti Rosei C, Caletti S, Trapletti V, Coschignano MA, Tiberio GAM, et al. Comparison between invasive and noninvasive techniques of evaluation of microvascular structural alterations. J Hypertens 2018; 36:1154–1163.